Semaglutide improves fatty liver and liver inflammation in people with HIV

Semaglutide may be a highly effective therapy for metabolic dysfunction-associated steatotic liver disease in people with HIV.

• Metabolomics algorithms can assess the severity of metabolic dysfunction-associated steatotic liver disease non-invasively.
• The potential for using metabolomic data to monitor disease progression during GLP-1RA therapy remains unexplored.
• The findings suggest a novel therapeutic approach for managing liver disease in individuals living with HIV.

Simplified